

# ForPatients

*by Roche*

Autism Spectrum Disorder

## Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03507569 BP40257

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03507569 BP40257**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 23 Years & <= 55 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---